Portal de investigación
A retrospective study of pregnancy-associated atypical hemolytic uremic syndrome
Fecha de publicación:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Huerta, A
- Arjona, E
- Portoles, J
- Lopez-Sanchez, P
- Rabasco, C
- Espinosa, M
- Cavero, T
- Blasco, M
- Cao, M
- Manrique, J
- Cabello-Chavez, V
- Suner, M
- Heras, M
- Fulladosa, X
- Belmar, L
- Peralta, C
- Castillo, L
- Arnau, A
- Praga, M
- de Cordoba, SR
Grupos
Abstract
Pregnancy-associated atypical hemolytic uremic syndrome (aHUS) refers to the thrombotic microangiopathy resulting from uncontrolled complement activation during pregnancy or the postpartum period. Pregnancy-associated aHUS is a devastating disease for which there is a limited clinical understanding and treatment experience. Here we report a retrospective study to analyze the clinical and prognostic data of 22 cases of pregnancy-associated aHUS from the Spanish aHUS Registry under different treatments. Sixteen patients presented during the first pregnancy and as many as nine patients required hemodialysis at diagnosis. Identification of inherited complement abnormalities explained nine of the 22 cases, with CFH mutations and CFH to CFHR1 gene conversion events being the most prevalent genetic alterations associated with this disorder (66%). In thirteen of the cases, pregnancy complications were sufficient to trigger a thrombotic microangiopathy in the absence of genetic or acquired complement alterations. The postpartum period was the time with highest risk to develop the disease and the group shows an association of cesarean section with pregnancy-associated aHUS. Seventeen patients underwent plasma treatments with a positive renal response in only three cases. In contrast, ten patients received eculizumab with an excellent renal response in all, independent of carrying or not inherited complement abnormalities. Although the cohort is relatively small, the data suggest that pregnancy-associated aHUS is not different from other types of aHUS and suggest the efficacy of eculizumab treatment over plasma therapies. This study may be useful to improve prognosis in this group of aHUS patients.
Datos de la publicación
- ISSN/ISSNe:
- 0085-2538, 1523-1755
- Tipo:
- Article
- Páginas:
- 450-459
- Factor de Impacto:
- 3,331 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
KIDNEY INTERNATIONAL ELSEVIER SCIENCE INC
Citas Recibidas en Web of Science: 74
Documentos
- No hay documentos
Filiaciones
Keywords
- cesarean section; complement; eculizumab; hemolytic uremic syndrome; postpartum
Proyectos asociados
RED DE INVESTIGACION COOPERATIVA DE CANCER
RD06/0020/0031 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2006
INTENSIFICACION DR. JAVIER DE LA RUBIA COMOS
Investigador Principal: JAVIER DE LA RUBIA COMOS
INT11/040 . 2012
RED TEMATICA DE INVESTIGACION COOPERATIVA EN CANCER (RTICC)
Investigador Principal: MIGUEL ÁNGEL SANZ ALONSO
RD12/0036/0014 . INSTITUTO DE SALUD CARLOS III . 2013
ESTUDIO DE MUTACIONES PREEXISTENTES EN LAS CÉLULAS MADRE HEMATOPOYÉTICAS EN PACIENTES CON NEOPLASIAS MIELOIDES RELACIONADAS CON LA TERAPIA.
Investigador Principal: GUILLERMO SANZ SANTILLANA
PI14/01649 . INSTITUTO DE SALUD CARLOS III . 2015
MÉDULA ÓSEA ARTIFICIAL PARA PERSONALIZAR EL TRATAMIENTO DE PACIENTES DE CÁNCERES DE SANGRE-TISSUE MIELOMA.
Investigador Principal: JOSE LUIS GOMEZ RIBELLES
2015_0800_CPC_GOMEZ . CONSELLERIA DE EDUCACION . 2016
INCORPORACIÓN GRUPOS CIBER. DR. SANZ
Investigador Principal: GUILLERMO SANZ SANTILLANA
CB16/12/00284 . INSTITUTO DE SALUD CARLOS III . 2017
Registro de Hemoglobinuria Paroxística Nocturna (HPN).
Investigador Principal: ISIDRO JARQUE RAMOS
ALE-ECU-2009-01 . 2010
ESTUDIO FASE 3, MULTICENTRICO, ALEATORIZADO, ABIERTO Y DE GRUPOS PARALELOS PARA VALORAR LA EFICACIA Y SEGURIDAD DE LENALIDOMIDA (REVLIMID) FRENTE A CLORAMBUCILO COMO TERAPIA DE PRIMERA LINEA EN PACIENTES ANCIANOS CON LEUCEMIA LINFOCITICA CRONICA DE CELULA S B NO TRATADOS PREVIAMENTE (ENSAYO ORIGIN).
Investigador Principal: MIGUEL ÁNGEL SANZ ALONSO
CC-5013-CLL-008 . 2010
ESTUDIO EN FASE I/II DE BÚSQUEDA DE DOSIS DE CH14.18/CHO EN INFUSIÓN CONTINUA COMBINADO CON ALDESLEUKINA (IL-2) SUBCUTÁNEA EN PACIENTES CON NEUROBLASTOMA PRIMARIO REFRACTARIO O EN RECAÍDA.
Investigador Principal: VICTORIA CASTEL SÁNCHEZ
012010 . 2012
ESTUDIO DE DISTINTAS SUBPOBLACIONES DE LINFOCITOS B CLONALES Y NORMALES EN INDIVIDUOS CON LEUCEMIA LINFÁTICA CRÓNICA
Investigador Principal: ISIDRO JARQUE RAMOS
ORF-ANT-2011-01 . 2013
Cita
Huerta A,Arjona E,Portoles J,Lopez P,Rabasco C,Espinosa M,Cavero T,Blasco M,Cao M,Manrique J,Cabello V,Suner M,Heras M,Fulladosa X,Belmar L,Sempere A,Peralta C,Castillo L,Arnau A,Praga M,de Cordoba SR. A retrospective study of pregnancy-associated atypical hemolytic uremic syndrome. Kidney Int. 2018. 93. (2):p. 450-459. IF:8,306. (1).